J. Goldman & Co LP Increases Stake in Geron Co. (NASDAQ:GERN)

J. Goldman & Co LP raised its holdings in shares of Geron Co. (NASDAQ:GERN) by 847.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,669,684 shares of the biopharmaceutical company’s stock after acquiring an additional 1,493,445 shares during the quarter. J. Goldman & Co LP owned approximately 0.28% of Geron worth $5,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Barclays PLC lifted its position in Geron by 114.9% during the third quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company’s stock valued at $5,902,000 after purchasing an additional 694,931 shares in the last quarter. Moody National Bank Trust Division lifted its position in shares of Geron by 76.6% during the 4th quarter. Moody National Bank Trust Division now owns 267,629 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 116,074 shares in the last quarter. Elmwood Wealth Management Inc. bought a new position in shares of Geron during the 4th quarter valued at approximately $93,000. Rovin Capital UT ADV increased its holdings in Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 3,660 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in Geron by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 403,703 shares of the biopharmaceutical company’s stock worth $1,429,000 after acquiring an additional 61,819 shares during the period. Institutional investors own 73.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Stifel Nicolaus reduced their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Barclays reissued an “overweight” rating and set a $4.00 price target (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Scotiabank lowered Geron from a “sector outperform” rating to a “sector perform” rating and dropped their price objective for the stock from $4.00 to $1.50 in a research note on Thursday. Finally, HC Wainwright reiterated a “neutral” rating on shares of Geron in a research report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Geron currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.06.

Geron Stock Performance

NASDAQ GERN opened at $1.19 on Friday. The business has a 50 day simple moving average of $1.49 and a two-hundred day simple moving average of $2.73. Geron Co. has a 1-year low of $1.17 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. The stock has a market capitalization of $754.74 million, a PE ratio of -3.70 and a beta of 0.76.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $39.60 million during the quarter, compared to analyst estimates of $49.88 million. During the same quarter last year, the business posted ($0.07) earnings per share. The firm’s revenue was up 12927.3% on a year-over-year basis. On average, research analysts predict that Geron Co. will post -0.25 EPS for the current fiscal year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.